EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Frequency of Clinically Relevant Drug–Drug Interactions Between Tyrosine Kinase Inhibitors and Proton Pump Inhibitors in Patients With Cancer Using Real‐World Data

Grietje van Elp iD, Maikel Borg iD, Jens H J Bos iD, Catharina C M Schuiling-Veninga, Katja Taxis iD, Frank G A Jansman iD

Basic & Clinical Pharmacology & Toxicology · 2026

DOI: 10.1111/bcpt.70317 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2026. Verfasst von Grietje van Elp und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Deventer Hospital, Deventer, the Netherlands. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms, Proton Pump Inhibitors, Tyrosine Kinase Inhibitors. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Proton pump inhibitors (PPIs) raise stomach pH, leading to reduced bioavailability of many tyrosine kinase inhibitors (TKIs), thereby affecting treatment outcomes. To what extent this interaction occurs in clinical practice remains underexplored.

Objective

To determine the frequency of clinically relevant interactions between TKIs and PPIs in clinical practice and the duration of concomitant prescription.

Methods

A retrospective observational study was performed using the IADB.nl prescription database. Clinically relevant drug–drug interactions between TKIs and PPIs were assessed using four drug compendia (i.e., KNMP Kennisbank, Health Base, Lexidrug and Merative Micromedex). Patients who were prescribed a TKI and PPI with a clinically relevant DDI concomitantly, between 1 January 2013 and 31 December 2024, were included. Concomitant prescription was defined as ≥ 7 days of simultaneous prescription.

Findings

In total, 60 TKIs were registered in the Netherlands; 19 TKIs had clinically relevant interactions reported by at least one compendium. Overall, 393 of 1759 (22.3%) TKI users had a clinically relevant interaction. The median duration of concomitant prescription was 43 days (IQR = 81), with 91.1% of episodes lasting at least 30 days.

Conclusion

PPIs and TKIs are frequently prescribed concomitantly in clinical practice. Prescribers should be more cautious when co‐prescribing PPIs with TKIs and adapt the dosing regimens when appropriate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeoplasmsProton Pump InhibitorsTyrosine Kinase InhibitorsAgedFemaleHumansMaleMiddle AgedDatabases, FactualDrug InteractionsNetherlandsRetrospective Studies

Stichwörter der Autor:innen

drug–drug interactionspharmacokineticsproton pump inhibitorsreal‐world datatyrosine kinase inhibitors

Substanzen

Antineoplastic AgentsProton Pump InhibitorsTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Deventer Hospital, Deventer, the Netherlands.
  • Unit of PharmacoTherapy, -Epidemiology and -Economics, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Groningen, the Netherlands.

ORCID-Profile: Grietje van Elp, Maikel Borg, Jens H J Bos, Katja Taxis, Frank G A Jansman

Zitieren

APA

van Elp, G., Borg, M., Bos, J. H. J., Schuiling-Veninga, C. C. M., Taxis, K., & Jansman, F. G. A. (2026). Frequency of Clinically Relevant Drug–Drug Interactions Between Tyrosine Kinase Inhibitors and Proton Pump Inhibitors in Patients With Cancer Using Real‐World Data. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70317

Vancouver

van Elp G, Borg M, Bos JHJ, Schuiling-Veninga CCM, Taxis K, Jansman FGA. Frequency of Clinically Relevant Drug–Drug Interactions Between Tyrosine Kinase Inhibitors and Proton Pump Inhibitors in Patients With Cancer Using Real‐World Data. Basic & Clinical Pharmacology & Toxicology. 2026. doi:10.1111/bcpt.70317

BibTeX
@article{vanElp2026,
  author = {van Elp, Grietje and Borg, Maikel and Bos, Jens H J and Schuiling-Veninga, Catharina C M and Taxis, Katja and Jansman, Frank G A},
  title = {Frequency of Clinically Relevant Drug–Drug Interactions Between Tyrosine Kinase Inhibitors and Proton Pump Inhibitors in Patients With Cancer Using Real‐World Data},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2026},
  doi = {10.1111/bcpt.70317}
}
Kostenlos starten →